Molecular Markers of Epithelial-to-Mesenchymal Transition Are Associated with Tumor Aggressiveness in Breast Carcinoma

被引:53
|
作者
Sethi, Seema [1 ]
Sarkar, Fazlul H. [1 ]
Ahmed, Quratulain [1 ]
Bandyopadhyay, Sudeshna [1 ]
Nahleh, Zeina A. [1 ]
Semaan, Assaad [2 ]
Sakr, Wael [1 ]
Munkarah, Adnan [3 ]
Ali-Fehmi, Rouba [1 ]
机构
[1] Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Karmanos Canc Inst, Detroit, MI 48201 USA
[3] Henry Ford Hlth Syst, Detroit, MI USA
来源
TRANSLATIONAL ONCOLOGY | 2011年 / 4卷 / 04期
关键词
NF-KAPPA-B; PROSTATE-CANCER CELLS; BASAL-LIKE PHENOTYPE; SIGNALING PATHWAY; VIMENTIN; EXPRESSION; IDENTIFICATION; INACTIVATION; PROGRESSION; METASTASIS;
D O I
10.1593/tlo.10244
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) is a transient process occurring during developmental stages and carcinogenesis, characterized by phenotypic and molecular alterations, resulting in increased invasive and metastatic capabilities of cancer cells and drug resistance. Moreover, emerging evidence suggests that EMT is associated with increased enrichment of cancer stem-like cells in neoplastic tissues. We interrogated the molecular alterations occurring in breast cancer using proposed EMT markers such as E-cadherin, vimentin, epidermal growth factor receptor (EGFR), platelet-derived growth factor (PDGF) D, and nuclear factor kappa B (NF-kappa B) to decipher their roles in the EMT and breast cancer progression. METHODS: Fifty-seven invasive ductal adenocarcinomas of the breast were assessed for the expression of E-cadherin, vimentin, EGFR, NF-kappa B, and PDGF-D using immunohistochemical analysis. Tumors were categorized into three groups: A (ER+, and/or PR+, HER-2/neu-), B (ER+, and/or PR+, HER-2/neu+), and C (triple-negative: ER-, PR-, and HER-2/neu-). Immunostained slides were microscopically evaluated and scored using intensity (0, 1+, 2+, and 3+) and percentage of positive cells, and data were statistically analyzed. RESULTS: Membranous E-cadherin was positive in all 57 cases (100%), whereas cytoplasmic E-cadherin was predominantly positive in groups B and C compared with group A (21%, 7%, and 0%, respectively). All group A cases were negative for vimentin and EGFR. There was statistically significant increased expression of vimentin (P < .0002), EGFR (P < .0001), and NF-kappa B (P < .02) in triple-negative cases when compared with groups A and B. CONCLUSIONS: Vimentin, EGFR, and NF-kappa B were significantly increased in triple-negative tumors, which is consistent with the aggressiveness of these tumors. These markers could be useful as markers for EMT in breast cancers and may serve as predictive markers for designing customized therapy in the future.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 50 条
  • [21] The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells
    Koelbl, Alexandra C.
    Jeschke, Udo
    Andergassen, Ulrich
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (08)
  • [22] Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition
    Lowes, Lori E.
    Allan, Alison L.
    ADVANCES IN CLINICAL CHEMISTRY, VOL 83, 2018, 83 : 121 - 181
  • [23] Epithelial-to-Mesenchymal Transition in Penile Squamous Cell Carcinoma
    Masferrer, Emili
    Ferrandiz-Pulido, Carla
    Masferrer-Niubo, Magali
    Rodriguez-Rodriguez, Alfredo
    Gil, Inmaculada
    Pont, Antoni
    Servitje, Octavi
    de Herreros, Antonio Garcia
    Lloveras, Belen
    Garcia-Patos, Vicenc
    Pujol, Ramon M.
    Toll, Agusti
    Hernandez-Munoz, Inmaculada
    JOURNAL OF UROLOGY, 2015, 193 (02): : 699 - 705
  • [24] Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
    Dongre, Anushka
    Rashidian, Mohammad
    Reinhardt, Ferenc
    Bagnato, Aaron
    Keckesova, Zuzana
    Ploegh, Hidde L.
    Weinberg, Robert A.
    CANCER RESEARCH, 2017, 77 (15) : 3982 - 3989
  • [25] Epithelial-to-Mesenchymal Transition in Metastasis: Focus on Laryngeal Carcinoma
    Goulioumis, Anastasios
    Gyftopoulos, Kostis
    BIOMEDICINES, 2022, 10 (09)
  • [26] In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
    Michela Bulfoni
    Lorenzo Gerratana
    Fabio Del Ben
    Stefania Marzinotto
    Marisa Sorrentino
    Matteo Turetta
    Giacinto Scoles
    Barbara Toffoletto
    Miriam Isola
    Carlo Alberto Beltrami
    Carla Di Loreto
    Antonio Paolo Beltrami
    Fabio Puglisi
    Daniela Cesselli
    Breast Cancer Research, 18
  • [27] In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
    Bulfoni, Michela
    Gerratana, Lorenzo
    Del Ben, Fabio
    Marzinotto, Stefania
    Sorrentino, Marisa
    Turetta, Matteo
    Scoles, Giacinto
    Toffoletto, Barbara
    Isola, Miriam
    Beltrami, Carlo Alberto
    Di Loreto, Carla
    Beltrami, Antonio Paolo
    Puglisi, Fabio
    Cesselli, Daniela
    BREAST CANCER RESEARCH, 2016, 18
  • [28] Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells
    Soon, Patsy S. H.
    Kim, Edward
    Pon, Cindy K.
    Gill, Anthony J.
    Moore, Katrina
    Spillane, Andrew J.
    Benn, Diana E.
    Baxter, Robert C.
    ENDOCRINE-RELATED CANCER, 2013, 20 (01) : 1 - 12
  • [29] Increased expression of epithelial-to-mesenchymal transition markers in geographic atrophy
    Tiwari, Anupama
    Bhutto, Imran Ahmed
    Edwards, Malia Michelle
    Grebe, Rhonda
    Lutty, Gerard A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [30] Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: Concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers
    Bhattacharya, Syamal D.
    Mi, Zhiyong
    Talbot, Lindsay J.
    Guo, Hongtao
    Kuo, Paul C.
    SURGERY, 2012, 152 (03) : 449 - 454